Trevi Therapeutics, Inc.
TRVI
$7.55
$0.060.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 32.59% | 17.96% | 20.70% | 5.18% | 28.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.26% | -3.66% | 37.05% | 55.74% | 58.54% |
| Operating Income | -3.26% | 3.66% | -37.05% | -55.74% | -58.54% |
| Income Before Tax | 0.31% | 5.12% | -46.08% | -72.13% | -72.26% |
| Income Tax Expenses | -162.50% | -37.50% | -11.11% | -138.46% | 73.33% |
| Earnings from Continuing Operations | 0.41% | 5.16% | -45.95% | -72.02% | -72.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.41% | 5.16% | -45.95% | -72.02% | -72.88% |
| EBIT | -3.26% | 3.66% | -37.05% | -55.74% | -58.54% |
| EBITDA | -3.27% | 3.69% | -37.17% | -55.95% | -58.73% |
| EPS Basic | 22.75% | 19.73% | -37.02% | -68.65% | -68.78% |
| Normalized Basic EPS | 22.75% | 19.71% | -37.14% | -68.87% | -68.50% |
| EPS Diluted | 22.75% | 19.73% | -37.02% | -68.65% | -68.78% |
| Normalized Diluted EPS | 22.75% | 19.71% | -37.14% | -68.87% | -68.50% |
| Average Basic Shares Outstanding | 29.01% | 18.18% | 6.56% | 1.97% | 2.37% |
| Average Diluted Shares Outstanding | 29.01% | 18.18% | 6.56% | 1.97% | 2.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |